Table 2.
Characteristics and results of the studies assessing physical performance with QOL
| Author, year | Country | No. of NHD pts | Frequency of NHD treatment | Study design, control group | Follow-up duration, months | Male % | Age, yearsa | Assessment and outcome | Effects NHD |
|---|---|---|---|---|---|---|---|---|---|
| Self-reported measurements | |||||||||
| Hall, 2012 [22] | USA, Canada | 45 | 6 times/wk., ≥6 h | RCT, CHD controls | 12 | 64 | 52 ± 14 | Physical health composite (PHC) by Short form-36 (SF-36), physical functional subscale (PF) | Change PHC after 12 mo NHD: 2.7 ± 1.4 vs control group: 2.1 ± 1.5, p = 0.75, Change PF after 12 mo NHD: − 3.1 ± 3.5 vs control group: 1.1 ± 3.6, p = 0.40. |
| Ok, 2014 [14] | Turkey | 247 | 3 times/wk., 7–8 h | Prospective, non-randomized case-control, CHD controls | 12 | 68 | 45 ± 14 | Physical functioning by SF-36 | Described: all dimensions were unchanged in the NHD group. Change in control group: vitality score decreased, 68.7 ± 24.3 to 64.4 ± 25.2, p = 0.01. |
| Eps, 2010 [24] | Australia | 63 | 3–5 times/wk., 6–10 h | Prospective cohort, no controls | 6–12 | 79 | 52 ± 13 | Physical functioning by Kidney disease QoL (KD-QoL) | Change in PF after 6–12 mo NHD: 60 to 75, p = 0.003. |
| Lockridge, 2004 [25] | Canada | 40 | 5–6 times/wk., 6–10 h | Prospective, longitudinal, no controls | 60 | 65 | 50 (23–81) | Physical composite score (PCS) by SF-36 | Change in overall mean PCS score after 5 yrs. NHD: 35.23 to 44.94, p = 0.007. |
| Fong, 2007 [27] | Canada | 26 | – | Cross-sectional, PD controls | – | 67 | 4912 | Physical component summary by KD-QoL | PCS in NHD: 55 ± 2.3 vs control group (PD): 52.3 ± 1.8, p = 0.35. |
aAge is given as mean ± SD or as median and IQR